Get startedLog in
    Picture of Kyowa Kirin logo

    4151 — Kyowa Kirin News Story

    0.000.00%
    jp flag iconLast trade - 00:00
    HealthcareBalancedLarge CapHigh Flyer
    All News

    Brief: KOMZIFTI Gets FDA Approval For Adults With Relapsed Or Refractory NPM1-Mutated AML

    Picture of Kyowa Kirin logoKyowa Kirin
    13/11/2025 18:43
    Nov 13 (Reuters) - Kura Oncology KURA.O:

KURA ONCOLOGY AND KYOWA KIRIN ANNOUNCE FDA APPROVAL OF KOMZIFTI™ (ZIFTOMENIB), THE FIRST AND ONLY ONCE-DAILY TARGETED THERAPY FOR ADULTS WITH RELAPSED OR REFRACTORY NPM1-MUTATED ACUTE MYELOID LEUKEMIA

Source text: ID:nGNX4LHHQf

Further company coverage: KURA.O

 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on Kyowa Kirin

    See all news